Aflibercept Biosimilar (Alvotech Swiss)

阿柏西普生物类似药 (Alvotech Swiss)

Report date: 2026/05/26 20:00:28

Base Information

Drug NameAflibercept Biosimilar (Alvotech Swiss)
Drug Alias NameMynzepliAVT-06AVT-29
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitorsPlacental Growth Factor inhibitors
TargetsVascular endothelial growth factor APlacental Growth Factor
Therapy Area/IndicationsDiabetic macular oedemaDiabetes ComplicationsVascular Diseases +[9] 
Global Approved IndicationsDiabetes ComplicationsChoroidal NeovascularizationRetinal Vein Occlusion +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/08/18
Country/TerritoryCzechiaUnited StatesSlovakia +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlvotech Swiss Ag
China Registration ClassN/A

Develop Information

Active CompaniesTeva Pharmaceutical Industries LtdAlvotech Swiss AgStada Arzneimittel Ag +[4] 
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaDiabetes ComplicationsVascular Diseases +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A